We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers’ Diarrhea
News

Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers’ Diarrhea

Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers’ Diarrhea
News

Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers’ Diarrhea

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers’ Diarrhea"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Santarus, Inc. has announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers’ diarrhea.

“The filing of the IND is an important milestone in the rifamycin SV MMX clinical program, and we look forward to moving forward with the development of rifamycin SV MMX for patients with travelers’ diarrhea.”

In the IND, Santarus proposed two international multicenter, randomized, double-blind studies, each with approximately 300 patients, to assess the efficacy and safety of rifamycin SV MMX 400 mg (2 x 200 mg) oral tablets taken twice daily (800 mg total daily dose) for three days versus placebo in the treatment of patients with travelers’ diarrhea. The primary endpoint of the Phase III clinical studies will be the time to last unformed stool (TLUS) and the studies will seek to demonstrate the superiority of rifamycin SV MMX to placebo.

Santarus expects to begin the first Phase III study in the first half of 2010. Assuming timely and successful completion, Santarus plans to initiate a second Phase III clinical study in travelers’ diarrhea in the first half of 2011.

Santarus has licensed exclusive rights to develop and commercialize rifamycin SV MMX in the U.S. from Cosmo Technologies Limited, a wholly owned subsidiary of Cosmo Pharmaceuticals SpA (SIX:COPN). Cosmo conducted the rifamycin SV MMX Phase II clinical program, which consisted of two studies in a total of 155 patients with infectious diarrhea in Mexico, Turkey and South Africa, under Clinical Trial Applications with regulatory authorities in those countries.

Based on a pre-IND meeting in early 2009, the FDA determined that rifamycin SV MMX is a new molecular entity (NME) in the U.S. and requested a full preclinical assessment prior to submitting an IND. These preclinical studies have recently been completed, allowing Santarus to proceed with the submission of the IND.

“The filing of the IND is an important milestone in the rifamycin SV MMX clinical program, and we look forward to moving forward with the development of rifamycin SV MMX for patients with travelers’ diarrhea,” said Gerald T. Proehl, president and chief executive officer.
Advertisement